SCHEMBL1450650

SCHEMBL1450650

Cc1cc(C)cc(N2CCN(C(=O)C(=O)c3cc(-c4ccccc4)[nH]c3C)CC2)c1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.49
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
HTR2A P28223 4/20 0.46
HTR2C P28335 4/20 0.46
SLC6A4 P31645 4/20 0.46
TACR3 P29371 1/20 0.45
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.44
ALOX15 P16050 1/20 0.42
LMNA P02545 1/20 0.41
NPY5R Q15761 1/20 0.41
P2RY12 Q9H244 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1451384 0.92 KMT2A (0.53) BRD4KMT2AMEN1HTR2AHTR2C
SCHEMBL1450195 0.91 KMT2A (0.54) BRD4KMT2AMEN1HTR2AHTR2C
SCHEMBL1450839 0.90 KMT2A (0.55) BRD4KMT2AMEN1HTR2AHTR2C
SCHEMBL1450141 0.87 KMT2A (0.64) BRD4KMT2AMEN1HTR2AHTR2C
SCHEMBL1450803 0.86 P2RY12 (0.52) BRD4KMT2AMEN1HTR2AHTR2C
SCHEMBL1450707 0.86 KMT2A (0.53) BRD4KMT2AMEN1HTR2AHTR2C
SCHEMBL1450101 0.86 KMT2A (0.67) KMT2AMEN1HTR2AHTR2CSLC6A4
SCHEMBL1450740 0.86 KMT2A (0.50) BRD4KMT2AMEN1HTR2AHTR2C
SCHEMBL1450146 0.85 KMT2A (0.52) BRD4KMT2AMEN1HTR2AHTR2C
SCHEMBL1451376 0.85 KMT2A (0.56) KMT2AMEN1TACR3ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2167487-B1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI SA (FR) 2015-02-18 EP claimed
US-7910576-B2 Pyrrole derivatives as P2Y12 antagonists SANOFI-AVENTIS (FR) 2011-03-22 US claimed
US-20100226918-A1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2010-09-09 US claimed
EP-2167487-B1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI SA (FR) 2015-02-18 EP disclosed
EP-2167487-B1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI SA (FR) 2015-02-18 EP disclosed
US-7910576-B2 Pyrrole derivatives as P2Y12 antagonists SANOFI-AVENTIS (FR) 2011-03-22 US disclosed
US-7910576-B2 Pyrrole derivatives as P2Y12 antagonists SANOFI-AVENTIS (FR) 2011-03-22 US disclosed
US-7910576-B2 Pyrrole derivatives as P2Y12 antagonists SANOFI-AVENTIS (FR) 2011-03-22 US disclosed
US-20100226918-A1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2010-09-09 US disclosed
US-20100226918-A1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2010-09-09 US disclosed
US-20100226918-A1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100226918-A1 PYRROLE DERIVATIVES AS P2Y12 ANTAGONISTS P2RY12, P2RY11, P2RY13 BRD4 1687/4885KMT2A 4670/4885MEN1 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.